Celgene Corp (CELG.O)
23 Sep 2014
|Market Cap (Mil.):||$73,706.84|
|Shares Outstanding (Mil.):||799.51|
- Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.
Sept 23 - Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.
LONDON - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.
LONDON, Aug 20 - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.
- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
* Raises 2014 revenue, adjusted earnings-per-share forecast
July 24 - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.
LONDON - An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being able to treat it, Danish scientists said on Tuesday.
* Scientists say finding is significant step in AIDS fight
- Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,928||+34.50|
|Eisai Co., Ltd (4523.T)||¥4,500||+57.00|
|Johnson & Johnson (JNJ.N)||$107.46||-0.42|
|Pfizer Inc. (PFE.N)||$30.05||-0.13|
|Novartis AG (NOVN.VX)||CHF87.75||-0.50|
|Merck & Co., Inc. (MRK.N)||$60.28||-0.30|
|Roche Holding Ltd. (ROG.VX)||CHF282.20||-1.00|
|Abbott Laboratories (ABT.N)||$42.50||-0.90|
|Sanofi SA (SASY.PA)||€87.41||-1.46|
|AstraZeneca plc (AZN.L)||4,414.00p||-163.50|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (CELG). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
"The Economy Matters" Report for CELGZ: the economy's impact on CELGZ's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.